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Abstract
Background: Surgical revision concepts for the treatment of aseptic humeral, femoral, and tibial diaphyseal
nonunion were evaluated. It was analyzed if the range of time to bone healing was shorter, and if clinical and
radiological long-term outcome was better following application of additional recombinant human Bone
Morphogenetic Protein-7 (rhBMP-7) compared to no additional rhBMP-7 use.
Methods: In a retrospective comparative study between 06/2006 and 05/2013, 112 patients diagnosed with aseptic
diaphyseal humerus (22 patients), femur (41 patients), and tibia (49 patients) nonunion were treated using internal
fixation and bone graft augmentation. For additional stimulation of bone healing, growth factor rhBMP-7 was
locally administered in 62 out of 112 patients. Follow-up studies including clinical and radiological assessment were
performed at regular intervals as well as after at least one year following nonunion surgery.
Results: One hundred and two out of 112 (humerus: 19, femur: 37, tibia: 47) nonunion healed within 12 months after
revision surgery without any significant differences between the cohort groups. According to the DASH outcome
measure for the humerus (p = 0.679), LEFS for the femur (p = 0.251) and the tibia (p = 0.946) as well as to the SF-12 for
all entities, no significant differences between the treatment groups were found.
Conclusions: Aseptic diaphyseal nonunion in humerus, femur, and tibia healed irrespectively of additional rhBMP-7
application. Moreover, the results of this study suggest that successful nonunion healing can be linked to precise
surgical concepts using radical removal of nonunion tissue, stable fixation and restoration of axis, length and torsion,
rather than to the additional use of signaling proteins.
Trial registration: This clinical trial was conducted according to ICMJE guidelines as well as to the approval of the
National Medical Board (Ethics Committee of the Bavarian State Chamber of Physicians; TRN: 2016-104) and has been
retrospectively registered with the German Clinical Trails Register (TRN: DRKS00012652).
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Background
Malunion or nonunion after fractures in long bones occurs
in about 5–10% of patients [1]. The rate of nonunion
ranges from 5% in the radius, 7% in the ulna, 9% in the hu-
merus, 12.5% in the femur, up to 45% in the tibia [2–4].
The relatively high incidence of nonunion in the tibia is re-
lated to the thin soft tissue envelope and the resulting insuf-
ficient blood supply. Open fractures of the tibia are often
associated with complex soft tissue lesions [5]. Another key
factor that delays bone healing may be the absence of load-
ing. Loading accelerates bone healing by increasing synthe-
sis, composition, organization, and mechanical properties
of bone matrix. Absence of loading may adversely affect dif-
ferentiation of mesenchymal cells, periosteum formation,
and osseous vascularization [6]. Development of nonunion
depends not only on the fracture pattern itself. Metabolic
and endocrine irregularities are also responsible for delay-
ing osseous healing [7] as well as iron deficiency anemia
[8], a variety of medication including non-steroidal anti-
inflammatory drugs, and chemotherapeutic medication.
Smoking and nicotine abuse directly correlate with delayed
bone healing and also increased failure rates after operative
nonunion revision using autologous bone grafting [9]. In
addition, increased patients’ age adversely affects physio-
logical osseous healing [10].
It is not possible to influence injury-related risk factors
for the development of aseptic shaft nonunion such as
open fractures or severe soft tissue injuries [11]. On the
other hand, treatment-related factors can be addressed.
Several factors originating from poor surgical technique
such as fracture gap, axis deviation, or the application of
small diameter nails and interlocking bolts result in in-
stability of the initial osteosynthesis [12].
A successful tool for filing traumatic, segmental bone
defects is the interposition of autologous bone graft [13].
In addition, it is well established that autologous bone
graft is beneficial for promoting bone healing specifically
in nonunion [14]. Various graft forms can be harvested
and utilized including non-vascularized or vascularized
grafts with or without mechanical, structural support
[15]. Although the stimulating effect on bone healing is
undisputed, adverse side effects such as donor site mor-
bidity specifically at the iliac crest, risk of infection, and
impaired graft incorporation remain problematic [16].
Indications and effects of administration of additional
growth factors such as recombinant human Bone Mor-
phogenetic Proteins (rhBMPs) in nonunion treatment
have not been clarified [17–19]. Currently, there is only
few comparative data on the use of rhBMPs for non-
union in long bones.
To our knowledge, this comparative study represents
the only clinical trial reporting aseptic diaphyseal non-
union in three different long bones treated at a single in-
stitution using stable internal fixation, and autologous
bone grafting, with and without use of additional rhBMP-
7. It was determined if the osseous healing in humeral,
femoral, and tibial shaft occurred more frequently, if the
range of time to bone healing decreased, and if the long-
term outcome was better with or without application of
additional rhBMP-7.
Methods
Between 06/2006 and 05/2013, a retrospective cohort study
was performed in a single level I trauma center. One-
hundred and twelve patients who were treated with long
bone fracture (22 x humerus, 41 x femur, and 49 x tibia)
and developed aseptic diaphyseal nonunion were included
(Table 1). Clinical signs of nonunion included persist-
ent pain, loss of function, osseous deformity, or hard-
ware loosening. Radiological nonunion formation was
determined as a lack of radiographic bridging in at
least three out of four cortices assessed on antero-
posterior and lateral conventional radiologic views. In
cases of doubt, a computed-tomography scan was per-
formed to detect radiological nonunion. Nonunion was
defined clinically and radiologically as absence of healing
at least six months after the initial operative fracture
stabilization or evident failure of treatment prior to that
[20]. Patients with congenital forms of nonunion or skel-
etal immaturity as well as patients with previous or con-
secutive positive bacterial cultures were excluded from the
study to restrict the study group to aseptic nonunion.
Fractures were classified according to the AO/OTA classi-
fication. A total of 62 patients obtained biological aug-
mentation using autologous bone grafting with
additional application of one unit of recombinant hu-
man Bone Morphogenetic Protein rhBMP-7 (Eptoter-
mine-α, OP-1®; Stryker Biotech, Kalamazoo, MI, USA)
according to manufacturer’s instructions (3.3 mg of lyophi-
lized rhBMP-7 combined with 6.7 mg of bovine collagen
type I) in each case. Surgical nonunion revision was per-
formed under the supervision of three senior surgeons
using similar concepts for nonunion treatment, which em-
phasized stable fixation, perfused bone ends, and autolo-
gous bone grafting with or without application of additional
rhBMP-7. The decision to use additional rhBMP-7 was
solely based on the intraoperative discretion of the treating
surgeon. RhBMP-7 was available in all cases and the use
was not dependent on the belief of the treating surgeon.
Also other variables taken from surgery such as patient,
fracture, and wound-related criteria did not influence the
decision to use rhBMP-7.
Surgical procedure
Humerus
In order to avoid shearing, torsional and distracting forces
after revision surgery, locking compression plate (LCP)
fixation in combination with complete opening and
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resection of the nonunion tissue and autologous cancel-
lous bone grafting was used in our standard treatment
protocol of atrophic humeral shaft nonunion (Fig. 1a–f )
[21, 22].
Femur
The gold standard for treatment of femoral shaft frac-
tures is anterograde intramedullary nailing (Fig. 4a–c)
[23]. In our treatment protocol, sequential reaming was
performed following removal of the primary, intrame-
dullary nail with the aim of inserting an exchange nail
with an increased diameter of 2 mm compared to the
initial nail diameter. It was ensured that each exchange
nail demonstrated cortical contact and a snug fit, and that
any fracture gap or dehiscence was avoided. For exchange
nailing, femoral nails were utilized which offered optional
interfragmentary compression. Following insertion of distal
interlocking screws, torsion of the femur was considered to
be correct if the projection of the femoral head was anterior
to the axis of the femoral shaft with two thirds of its cir-
cumference [24].
Tibia
Anterograde intramedullary nailing was considered the
treatment of choice in tibial shaft fractures [25]. In ac-
cordance to the treatment concept for aseptic femoral
shaft nonunion, revision surgery of aseptic tibial shaft
nonunion included reamed intramedullary exchange
nailing (Fig. 6a–c) [26, 27].
Autologous cancellous bone grafting
Autologous bone graft and stable plate fixation was uti-
lized for treatment of traumatic, segmental bone defects
[28]. Surgical nonunion therapy includes radical resection
Table 1 Patients’ data overview
Humerus Femur Tibia
with rhBMP-7 without rhBMP-7 with rhBMP-7 without rhBMP-7 with rhBMP-7 without rhBMP-7
Group size 13 9 28 13 21 28
Gender: Male / female 7 / 6 6 / 3 17 / 11 11 / 2 14 / 7 20 / 8
Age [years] 49.0 ± 4,7 51.0 ± 4.2 55.2 ± 2.6 42.4 ± 3.8 51.6 ± 2.7 42.3 ± 2.6
Closed / open fracture 11 / 2 7 / 2 24 / 4 10 / 3 14 / 7 18 / 10
Nicotine abuse 6 2 4 1 10 6
Diabetes mellitus 2 0 2 1 4 0
Steroid therapy 0 0 1 0 0 0
Charlson comorbidity index [33] 0.23 ± 0.12 0.33 ± 0.17 0.41 ± 0.15 0.31 ± 0.17 0.38 ± 0.16 0.14 ± 0.08
Period of time between index
operation and revision surgery [months]
14.8 ± 3.8 11.7 ± 1.1 10.3 ± 2.6
Results are presented as mean ± standard error of the mean (SEM) or median
Fig. 1 a 36-year-old patient suffering a diaphyseal humerus fracture. b Nonunion 9 months after index operation including closed reduction and
internal fixation using a retrograde intramedullary nail. c Patient rejected open reduction procedure and therefore, closed exchange nailing using
a reamed anterograde intramedullary nail with a larger diameter was performed. d Persistent nonunion 11 months after primary revision surgery.
e Secondary revision including resection of the nonunion site, shortening of the humeral shaft, application of reaming graft, and rigid LCP fixation. f
Complete nonunion healing 6 months after secondary operative revision
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of atrophic and fibrotic tissue. For operative stabilization
of the nonunion site, it is necessary to apply bridging fix-
ation and to achieve high cortex to cortex stability. These
are the prerequisites to promote angiogenesis, migration
of osteogenic cells, and integration of autologous bone
graft.
Osteogenesis of the bone graft is progressing independ-
ently from host- driven osteogenesis. Bone graft cells are
competent to promote new bone formation. Thus, autolo-
gous bone graft is successfully used to promote bone heal-
ing, to fill bone defects, and to restore bone length and
alignment.
Follow-up
After discharge, patients were followed up clinically and
radiologically at regular office visits, six weeks, three
months, six months following nonunion revision, and at
the most recent visit in the outpatient department of our
hospital at least one year after revision surgery. Each pa-
tient was assessed using the following parameters: Ability
for weight bearing without pain for the lower limb non-
union, stability at the nonunion site, formation of callus at
all four cortices, and elimination of fracture lines [29].
The influence of the treatment outcome on patients sub-
jective and objective health status was assessed using the
DASH outcome measure (Disabilities of the Arm, Shoul-
der and Hand) [30], the Lower Extremity Functional Score
(LEFS) [31], and the SF-12 score [32]. The DASH de-
scribes the functionality of the upper extremity (maximum
score of 100 indicates a greater disability) and the LEFS
the functionality of the lower extremity (maximum score
of 80 equates to the best functional outcome) [30, 31].
The SF-12 assesses patients’ physical and mental state and
includes the physical component summary (PCS) and the
mental component summary (MCS) (maximum score of
100 equates to the best outcome) [32]. Comorbidities were
assessed using the Charlson comorbidity index [33].
Statistical analysis
Statistical analysis was performed using IBM SPSS® Sta-
tistics for Windows 19.0 (IBM Corp., Armonk, New
York, USA). Results of this study are presented as mean
values ± standard error of the mean (SEM) or median.
Significance was statistically calculated based on the
Mann Whitney Test. A result was considered to be sta-
tistically significant with p-value <0.05.
Results
The cohort groups consisted of 76 male and 38 female
patients with the age of 48.8 +/− 2.1 years (range 18–
78 years).
Humerus
Twenty-two patients with a median age of 49.8 +/−
3.2 years (range 21–78 years) developed a humeral shaft
nonunion (Fig. 1a–f ). The median diameter of the ex-
tracted humeral nails was 8 mm (range 7–9 mm). Thir-
teen out of 22 patients were treated using rigid LC
plating with autologous cancellous bone grafting, and
additional application of rhBMP-7. The remaining 9 pa-
tients received LC plaiting combined with autologous
cancellous bone grafting alone. Hereby, the cohort
groups consisted of 13 patients (7 male and 6 female)
with a median age of 49.0 +/− 4.7 years (range 21–
78 years) in the group with rhBMP-7, and 9 patients (6
male and 3 female) with a median age of 51.0 +/− 4.2
(range 35–73 years) years in the group without rhBMP-
7. Two fractures of both cohort groups were classified
as open fractures. The median range of time between
initial fracture stabilization and surgical revision was
14.8 +/− 3.8 months (range 6–29 months). The follow-
ing comorbidities were found in the study groups:
Nicotine abuse was found in 6 patients (46%) with
rhBMP-7, and in 2 patients (22%) without rhBMP-7.
Two patients (15%) with rhBMP-7 were treated with
Diabetes mellitus, but no patient without rhBMP-7.
Steroid therapy was performed in none of these pa-
tients. The Charlson comorbidity index [33] was 0.23
+/− 0.12 points in the group with rhBMP-7 and 0.33
+/− 0.17 points in the group without rhBMP-7
(p = 0.62). Nineteen out of 22 nonunion healed within
12 months after revision surgery. In two patients of the
group with use of additional rhBMP-7, no bone healing
was found, whereas in all patients without rhBMP-7
complete nonunion healing was achieved. In one pa-
tient of the cohort group treated with LC plating, and
autologous cancellous bone grafting but without add-
itional rhBMP-7, a re-fracture occurred after a fall. The
range of time between revision surgery and complete
nonunion healing was 12.6 +/− 2.7 months (range 3–
19 months) in all patients, 11.5 +/− 2.7 months (range
3–19 months) in the group with additional rhBMP-7
application, and 13.5 +/− 1.4 months (range 6–
17 months) in the group without use of additional
rhBMP-7 (p = 0.798) (Table 2; Fig. 2).
According to the DASH outcome measure, no sig-
nificant differences between the cohort groups were
found (with rhBMP-7: 43.2 +/− 10.2 points; without
rhBMP-7: 50.9 +/− 12.4 points, p = 0.679) (Fig. 3).
According to the PCS of SF-12 score, no significant
difference was observed between those groups (with
rhBMP-7: 33.2 +/− 3.5 points; without rhBMP-7: 32.0
+/− 6.6; p = 0.873). Similar results were detected for
the MCS of the SF-12 score (51.1 +/− 5.0 points in
the cohort group with rhBMP-7, 44.0 +/− 4.4 points
in the group without rhBMP-7; p = 0.34) (Table 2).
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Femur
Forty-one patients (median age 51.2 +/− 2.3 years; range
22–78; 27 male, 14 female) were treated with the diag-
nosis of a femoral shaft nonunion (Fig. 4a–c) and were
available for follow-up. Twenty-eight out of those 41 pa-
tients were treated with application of additional
rhBMP-7 whereas the remaining 13 patients did not re-
ceive any additional rhBMP-7. Hereby, the cohort
groups consisted of 28 patients (17 male and 11 female)
with a median age of 55.2 +/− 2.6 years (range 22–
78 years) in the group with rhBMP-7, and 13 patients
(11 male and 2 female) with a median age of 42.4 +/−
3.8 (range 22–67 years) years in the group without
rhBMP-7. Four fractures in the group with rhBMP-7,
and three fractures in the group without rhBMP-7 were
classified as open fractures. The median period of time
between initial fracture stabilization and surgical revision
was 11.7 +/− 1.1 months (range 6–26 months). The fol-
lowing comorbidities occurred in the treatment groups:
Nicotine abuse was found in 4 (14%) of the patients with
rhBMP-7, and in 1 (8%) of the patients without rhBMP-
7. Two patients (7%) with rhBMP-7 and 1 patient (8%)
without additional rhBMP-7 were treated with Diabetes
mellitus. Steroid therapy was performed in 1 patient
(4%) with rhBMP-7, but in none of the patients in the
cohort group without rhBMP-7. The Charlson comor-
bidity index was 0.41 +/− 0.15 points in the group with
rhBMP-7, and 0.31 +/− 0.17 points in the group without
rhBMP-7 (p = 0.68).
Thirty-seven out of 41 femoral shaft nonunions healed
after revision surgery. The median nail diameter of the
extracted nails was 10 mm (range 9–13 mm) and the
median diameter of the inserted exchange nails was
12 mm (range 10–16 mm). In 3 patients with application
of additional rhBMP-7, and in 1 patient of the group
without use of rhBMP-7 no bone healing was found. In
1 patient treated with rigid plate fixation and application
of rhBMP-7, screw loosening was observed. The range
of time between revision surgery and osseous healing
was 17.0 +/− 0.7 months (range 3–25 months) in all pa-
tients, 16.9 +/− 2.2 months (range 3–25 months) in the
group with additional rhBMP-7, and 17.2 +/− 1.9 months
(range 10–20 months) in the group without additional
rhBMP-7 (p = 0.922) (Table 2; Fig. 2).
At the most recent follow-up, the functional outcome
according to the LEFS was 45.9 +/− 5.7 points in the
group with rhBMP-7, and 30.8 +/− 6.2 points in the
group without rhBMP-7 demonstrated no significant dif-
ference (p = 0.251) (Fig. 5). According to the PCS of the
SF-12 score no significant differences was observed be-
tween those both groups (with rhBMP-7: 39.7 +/− 3.0
points; without rhBMP-7: 33.9 +/− 1.7; p = 0.404). The
results according to the MCS of the SF-12 also demon-
strated no significant differences (with rhBMP-7: 50.2
+/− 2.2 points; without rhBMP-7: 41.6 +/− 6.3 points;
p = 0.138) (Table 2).
Tibia
Forty-nine patients (median age 46.3 +/− 2.0 years;
range 21–77; 34 male, 15 female) suffered tibial shaft
Table 2 Functional and radiological results: Overview
Humerus Femur Tibia
with rhBMP-
7
without
rhBMP-7
with
rhBMP-7
without
rhBMP-7
with
rhBMP-7
without
rhBMP-7
Radiological bone healing within 12 months after
revision [n]
11 / 13 8 / 9 25 / 28 12 / 13 19 / 21 28 / 28
Range of time to bone healing [months] 11.5 ± 2.7 13.5 ± 1.4 16.9 ± 2.2 17.2 ± 1.9 12.0 ± 0.6 13.1 ± 1.4
DASH [points] [30] 43.2 ± 10.2 50.9 ± 12.4 - - - -
LEFS [points] [31] 45.9 ± 5.7 30.8 ± 6.2 50.3 ± 5.0 49.9 ± 3.9
PCS of SF-12 score [points] [32] 33.2 ± 3.5 32.0 ± 6.6 39.7 ± 3.0 33.9 ± 1.7 35.8 ± 3.4 39.0 ± 2.4
MCS of SF-12 score [points] [32] 51.1 ± 5.0 44.0 ± 4.4 50.2 ± 2.2 41.6 ± 6.3 52.6 ± 2.4 46.8 ± 2.9
Results are presented as mean ± standard error of the mean (SEM) or median
Fig. 2 Range of time to bone healing [months] depending on the
application of additional rhBMP-7
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nonunion and were available for follow-up (Fig. 6a–c).
Twenty-one out of 49 patients were treated with applica-
tion of additional rhBMP-7, whereas the remaining 28 pa-
tients received surgical treatment without additional
rhBMP-7. Hereby, the cohort groups consisted of 21 pa-
tients (7 female, 14 male; median age of 51.6 +/− 2.7 years,
range 29–77 years) in the group with rhBMP-7, and 28
patients (20 male and 8 female; median age of 42.3 +/−
2.6, range 21–60 years) years in the group without
rhBMP-7. Seven fractures in the group with rhBMP-7,
and 10 fractures in the group without rhBMP-7 were clas-
sified as open fractures. The median period of time be-
tween initial fracture stabilization and surgical revision
was 10.3 +/− 2.6 months (range 6–24 months). The fol-
lowing comorbidities were found in the study groups:
Nicotine abuse was found in 10 patients (48%) with
rhBMP-7, and in 6 patients (21%) without rhBMP-7. Four
patients (19%) with use of additional rhBMP-7 but none
of the patients without additional rhBMP-7 suffered from
Diabetes mellitus. Steroid therapy was performed in none
of these patients. The Charlson comorbidity index was
0.38 +/− 0.16 points in the group with rhBMP-7, and 0.14
+/− 0.08 points in the cohort group without rhBMP-7
(p = 0.17). Forty-seven out of these 49 tibial shaft non-
unions healed within 12 month after revision surgery. In 1
patient out of the group with use of additional rhBMP-7
no bone healing was found whereas in all patients without
utilization of rhBMP-7 complete nonunion healing was
achieved. The range of time between revision surgery and
complete nonunion healing was 12.6 +/− 1.0 month
(range 3–22 months) in all patients, 12.0 +/− 0.6 months
(range 3–20 months) in the group with additional
rhBMP-7, and 13.1 +/− 1.4 months (range 4–22 months)
in the group without additional rhBMP-7 (p = 0.608)
(Table 2; Fig. 2).
At the most recent follow-up, the functional outcome
according to the LEFS was 50.3 +/− 5.0 points in the
Fig. 3 Functional outcome according to the DASH outcome
measure [30] at least 12 months after surgical revision of aseptic
diaphyseal humeral nonunion with or without application of
additional rhBMP-7
Fig. 4 a 52-year-old man developed a diaphyseal femoral nonunion
following anterograde intramedullary nailing of a femoral shaft fracture
using a nail with thin diameter and thin locking screws resulting in
torsional instability. b Nonunion revision using a reamed anterograde
nail with a larger diameter and locking screws with a larger diameter as
well as application of intramedullary reaming graft. c Complete implant
removal after nonunion healing 12 months after revision surgery
Hackl et al. BMC Musculoskeletal Disorders  (2017) 18:342 Page 6 of 10
group with rhBMP-7, and 49.9 +/− 3.9 points in the group
without rhBMP-7, and did not demonstrate any significant
difference (p = 0.946) (Fig. 5). According to the PCS of
SF-12 score, no significant difference was observed be-
tween the treatment groups (with rhBMP-7: 35.8 +/− 3.4
points; without rhBMP-7: 39.0 +/− 2.4; p = 0.438). The re-
sults according to the MCS of the SF-12 also demon-
strated no significant difference (with rhBMP-7: 52.6 +/−
2.4 points; without rhBMP-7 46.8 +/− 2.9 points;
p = 0.148) (Table 2).
Discussion
Nonunion in long bones occurs most commonly in the
tibia, but also the femur and the humerus are affected.
The current study is probably one of the largest to com-
pare the clinical efficacy of application of additional
rhBMP-7 in operative revision concepts including resec-
tion of the nonunion site, restoration of axis and tor-
sional deviation, stable fixation and autologous bone
grafting of diaphyseal aseptic nonunion in those three
different long bones. At least one year after revision sur-
gery, radiological results and functional outcome accord-
ing to the DASH outcome measure in the humerus, to
the LEFS in the femur and the tibia, as well as to the SF-
12 for all three entities, did not demonstrate significant
differences between the cohort groups. Therefore, this
study provides clinical support to earlier in vitro data on
the osteogenetic activity of rhBMP-7 [34].
In recent literature, no robust data concerning long bone
nonunion in the upper and lower limbs is available. Only
few retrospective studies and some case reports about non-
union in long bones have been reported [35–37]. Due to
the complex pattern of nonunion, comparison of the mo-
dalities of effective treatment is difficult. The two leading
principles of nonunion treatment include achieving stability
with stable internal fixation as well as improving bone biol-
ogy. A retrospective review described a case series of nine
humerus nonunion treated with a locking plate, of which
eight received application of additional rhBMP. At a me-
dian follow-up of 16 months, seven out of eight patients
demonstrated clinical and radiographic signs of union.
Complications included postsurgical superficial erythema
that resolved after a short course of antibiotic medication
[38]. A retrospective comparison of rhBMP and autogenous
iliac crest bone grafting evaluated a series of 89 patients
with 93 nonunion in humerus, femur, and tibia and found a
healing rate of 68.4% in 19 rhBMP sites, and 85.1% in 74
autograft sites [39]. Postoperative infection after autologous
bone grafting occurred in 16.2% and therefore, was not sig-
nificantly higher than in 5.3% following use of additional
rhBMP. In a retrospective case series of nine tibial non-
union, bony healing was achieved with a mean time to
union of 27.6 weeks using reamer-irrigator-aspirator au-
togenous bone graft, rhBMP, and intramedullary nail
Fig. 6 a 48-year-old man with atrophic tibial shaft nonunion 8 months
after intramedullary nailing. Curved fibula indicated mechanical blockage
and prevented dynamization and compression of the nonunion site
resulting in dehiscence of the fracture ends. b Reamed anterograde
intramedullary exchange nailing including fibula osteotomy. c Osseous
healing and complete implant removal one year after reamed
exchange nailing
Fig. 5 Functional outcome according to the LEFS [31] at least
12 months after surgical revision of aseptic diaphyseal femoral and
tibial nonunion with or without application of additional rhBMP-7
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fixation [40]. In terms of lower limb nonunion, a retro-
spective review included 21 operative revisions of tibia and/
or fibula nonunion treated with rhBMP, of which 81%
healed [41].
Additional concepts to stimulate bone healing focused on
topical application of growth factors such as rhBMPs.
RhBMPs promote osteogenesis by enhancing cell signaling,
chemotaxis, mitosis, and cellular differentiation and
thereby, are beneficial in promoting osteoinduction [14, 15].
Several studies have reported positive effects of rhBMPs
on healing of fractures, soft tissue injuries as well as non-
union [14]. The most widespread application of rhBMPs
included topical application of rhBMP-7 for spinal fusion
surgery, and for tibial shaft nonunion. Previously, adverse
effects of rhBMPs on carcinogenesis following topical ap-
plication of rhBMPs were described. Cahill et al. reported
increased risk for postoperative cancer in patients who
were treated with spinal arthrodesis and additional use of
rhBMP-7 [42]. However, increased cancer risk was not
confirmed in recent studies, in which long bone non-
unions were treated with additive BMP administration.
In our study, the majority of patients who was treated
with additional rhBMP-7 demonstrated successful heal-
ing of nonunion. Although the results of our study con-
firmed earlier investigations [43], no significant
differences for the overall rate of nonunion healing were
found between the cohort groups. In addition, neither
the period of time between initial fracture stabilization
and surgical revision, nor the range of time between re-
vision surgery and nonunion healing demonstrated sig-
nificant differences between the cohort groups.
A few case reports described an inflammatory reaction
following application of rhBMPs for nonunion treatment
[44]. Development of ectopic ossifications occurred in
one case of distal humeral nonunion [45]. Therefore,
these authors recommended caution when using
rhBMP-7 in the upper extremity in regions with close
proximity of soft tissue to bone, and in regions where
loss of motion would be problematic. Recently, it was re-
ported that ectopic ossification after the use of rhBMP-7
in nonunion was common but did not compromise the
final clinical outcome in most cases, and affected only
male patients [46]. Focusing on the structure of the treat-
ment groups in the current study, we were not able to
confirm these previous findings, and furthermore, there
was no relevant difference concerning comorbidities ac-
cording to the Charlson comorbidity index between the
cohort groups. In addition, no comprehensive data con-
cerning the development of ectopic ossifications or in-
flammation following application of additional rhBMP-7
was found.
In contrast to earlier studies, the latest research rec-
ommended the early use of rhBMPs in treatment of
nonunion even in terms of economic aspects specifically
in cases with increased severity of osseous and soft tis-
sue damage [14, 15, 47]. Due to the results of the current
study, we cannot recommend the use of additional rhBMP
in revision surgery as an effective additive treatment tool
for aseptic nonunion in humerus, femur, and tibia shaft.
Single autologous bone grafting may be as beneficial, but
much less expensive. Although rhBMP-7 was available in
our institution, we were not able to prove that its add-
itional use was essential to obtain osseous union.
The limitations of this study include the variety of age
of patients, initial fracture treatment, period of time be-
tween fracture treatment and nonunion treatment as
well as the sequential nature of the two cohort groups.
The decision to utilize rhBMP-7 was dependent on the
intraoperative assessment, and the discretion of the
treating surgeon, and was not subject to randomized or
blinded protocol. On the other hand, all patients were
managed with a standard treatment protocol in the same
hospital by the same group of surgeons.
Conclusions
Application of additional rhBMP-7 for treatment of
aseptic diaphyseal long bone nonunion in humerus,
femur, and tibia did not prove to promote or accelerate
bone healing in this study. In contrast, the results sug-
gest that successful bone healing of aseptic long bone
shaft nonunion is more dependent on a standard non-
union treatment protocol using radical resection of non-
union tissue, restoration of axis and torsion, and stable
osteosynthesis than on additional application of signaling
proteins.
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